Omega-3s and Biological Aging: What the Evidence Actually Shows

Open a bathroom cabinet in almost any country and you'll probably find a bottle of fish oil. It's the supplement people take to protect the heart and slow aging. The biology behind that hope is real. The trial results are messier than the label suggests. In 2025 a careful study even measured whether omega-3 can slow the body's aging clocks. Here's what the science actually says.

Where we stand. Most of us were raised to believe omega-3 is simply good for us. We are not here to criticize the supplement. Our question is narrower: judged strictly through the lens of aging, does it actually do anything? We grade the evidence as emerging because that is honestly what the research supports. If this reads as contrary to what you've heard about fish oil, that is the point.

Why This Matters

Omega-3 is one of the most-taken supplements on Earth, second only to the multivitamin in many surveys. Fish oil is a multi-billion-dollar category. The pitch is simple: these are the healthy fats in salmon, the ones your body can't make on its own, the ones linked to long-lived people who eat a lot of seafood.

The biology is genuinely good. Omega-3s sit inside your cell membranes. They calm inflammation. People with more omega-3 in their blood tend to live longer. That's a strong starting hand.

Then the large trials arrived, and most of them came back null. At the standard one-gram-a-day dose, omega-3 did not prevent heart attacks and strokes in the big prevention studies. That gap, between a promising biology and disappointing hard-outcome trials, is the whole story. It's also a useful lesson in how to read any longevity claim.

Let me walk through it in layers: where the omega-3 story came from, what omega-3 does in the body, what the blood-level and aging data show, what the rigorous trials found, and how to think about a capsule.

Where the Omega-3 Story Came From

Before the trials, there was a story, and it's worth knowing, because it shaped everything that followed.

In the 1970s, two Danish researchers, Hans Olaf Bang and Jorn Dyerberg, traveled to northwest Greenland to study the Inuit. The Inuit ate enormous amounts of seal, whale, and fish, a diet heavy in animal and marine fat, and yet they were reported to have very little heart disease. Bang and Dyerberg measured the fats in their blood and found high levels of the marine omega-3 EPA, far higher than in mainland Danes (American Journal of Clinical Nutrition, 1975; Acta Medica Scandinavica, 1976). In 1978, with the pharmacologists Salvador Moncada and John Vane, they proposed a mechanism in The Lancet: the Inuit's high EPA and low omega-6 arachidonic acid could tilt the blood toward an "antithrombotic state," making clots, and the heart attacks they cause, less likely. A 1980 survey of about 1,800 people in Greenland's Upernavik district reported the same pattern, a "lower frequency or absence of acute myocardial infarction" (Acta Medica Scandinavica, 1980).

That was the seed: a fatty diet linked to healthy hearts, with a clean molecular story to explain it. It launched fifty years of omega-3 research.

Archival Photograph, 1959

Two other threads turned that seed into a global supplement habit. The first was a worry about the modern diet. Over the 20th century, American consumption of soybean oil rose more than a thousandfold, and the omega-6 fat linoleic acid climbed from about 2.8 to 7.2 percent of daily energy (Blasbalg and colleagues, American Journal of Clinical Nutrition, 2011). As omega-6 went up, estimated omega-3 levels in body tissue fell, with one modeled tissue omega-3 index dropping from about 8 to under 4 across the century. Researchers like Artemis Simopoulos argued that humans evolved on a diet with a roughly one-to-one ratio of omega-6 to omega-3, while modern Western diets run closer to 16-to-1, leaving us "deficient in omega-3 fatty acids" (Biomedicine & Pharmacotherapy, 2002). Take a population that seemed protected by marine fat, add a story that modern eaters are starved of it, and a supplement sells itself. (The ratio argument is a hypothesis, not settled fact, and it has critics, but it shaped how a generation thought about fish oil.)

The second thread was a trial that seemed to seal it. In 1999, the Italian GISSI-Prevenzione study gave 11,324 heart-attack survivors one gram of omega-3 a day and reported a real benefit: a 10 to 15 percent drop in the combined risk of death, heart attack, and stroke, depending on the analysis, and a larger drop in cardiovascular death (The Lancet, 1999). For years, that result was the headline. Fish oil worked.

Then the story got complicated, in two ways at once. First, when researchers went back to the original Inuit data, it didn't hold up. A 2014 reappraisal in the Canadian Journal of Cardiology found that Bang and Dyerberg's famous studies "did not investigate the prevalence" of heart disease at all. They measured blood fats and took the low heart-disease rate from secondhand reports. Most careful studies since have found that Inuit populations have coronary disease about as often as everyone else (Fodor and colleagues, 2014). The founding observation, it turned out, was thinner than fifty years of citations made it look. Second, when modern medicine ran the big, rigorous prevention trials at that same one-gram dose, they mostly came back null, as the next sections cover.

So the omega-3 story moved from strong belief to open question. The biology is still real. The supplement is still safe. But the confident headline, that fish oil protects your heart and slows your decline, has quietly downgraded to "we are still figuring this out." That is the honest state of the evidence, and it is the lens we use for the rest of this article.

A note on method: we are not out to praise fish oil or bury it. We are asking one narrow question, whether it measurably affects aging, and following the data wherever it goes. The reputation came first. The rigorous tests came later. When the two disagree, we side with the tests, and right now the tests say emerging.

What Omega-3s Actually Do in the Body

"Omega-3" refers to a family of polyunsaturated fats. Two of them matter most for health: EPA and DHA. Both come mainly from the sea, oily fish and the algae the fish eat. A third, ALA, comes from plants like flaxseed, and your body converts only a small fraction of it into EPA and DHA.

DHA is structural. It's built into the membranes of your cells, and it's especially concentrated in the brain, the retina, and the membranes around your mitochondria. EPA leans more toward signaling. Your body uses it to make molecules that actively switch off inflammation once it has done its job. This matters because the slow, smoldering inflammation of aging, sometimes called inflammaging, is one of the drivers behind inflammation and aging.

This is why researchers measure something called the Omega-3 Index: the percentage of EPA plus DHA in your red blood cell membranes. Unlike a single blood draw that reflects what you ate yesterday, the Omega-3 Index reflects months of intake. It behaves like a body-composition reading for fat, and it turns out to track with how long people live.

That biomarker is where the aging story really begins.

The Blood-Level Story: Omega-3 and How Long People Live

Start with the Framingham Heart Study, the long-running cohort that taught us much of what we know about heart disease. A 2018 analysis in the Journal of Clinical Lipidology, led by William Harris, measured the Omega-3 Index in about 2,500 participants. The people in the highest group, an index above 6.8 percent, had a 34 percent lower risk of death from any cause, and a 39 percent lower risk of developing cardiovascular disease, than those in the lowest group, below 4.2 percent.

A much bigger pooled study made the same point. In 2021, again with Harris involved, Nature Communications published a combined analysis of 17 prospective cohorts: 42,466 people followed for a median of 16 years, during which 15,720 died. Those with the highest blood levels of long-chain omega-3 had a 15 to 18 percent lower risk of death from any cause than those with the lowest. Notably, the plant-based ALA showed no such link. The marine fats, EPA and DHA, carried the signal.

There's even a thread connecting omega-3 to the biological machinery of aging itself. A 2010 study in JAMA, led by Ramin Farzaneh-Far, followed 608 patients with coronary heart disease in the Heart and Soul Study and measured their telomeres, the protective caps on chromosomes that shorten as cells age. Each one-standard-deviation increase in DHA plus EPA was associated with a 32 percent lower odds of rapid telomere shortening.

Here's the catch that runs through this entire section: all of it is observational. People with high omega-3 levels eat more fish, and they tend to differ from low-omega-3 people in dozens of ways, more exercise, more income, fewer cigarettes. Association is not causation. The cleanest way to test causation is a randomized trial, and when researchers ran one on the telomere question, the result cooled the enthusiasm.

In a 2013 randomized controlled trial in Brain, Behavior, and Immunity, Janice Kiecolt-Glaser and colleagues gave 106 adults omega-3 or placebo. The supplement did lower oxidative stress: a marker called F2-isoprostanes dropped 15 percent. But the differences in telomere length, and in telomerase, the enzyme that maintains telomeres, were not statistically significant. The blood marker moved. The telomere marker didn't.

The Newest Test: Can Omega-3 Slow the Epigenetic Clock?

The most interesting recent result tries to answer the aging question head-on.

In 2025, Nature Aging published an analysis from the DO-HEALTH trial, led by Heike Bischoff-Ferrari. DO-HEALTH was a large European trial that gave older adults vitamin D, omega-3, a home exercise program, or combinations of the three. This particular analysis looked at 777 participants and asked whether any of those treatments slowed four "epigenetic clocks," which estimate biological age from chemical tags on DNA. The clocks have names: PhenoAge, GrimAge, GrimAge2, and DunedinPACE.

Omega-3 alone, at one gram a day over three years, slowed three of them: PhenoAge, GrimAge2, and DunedinPACE. The size of the effect was small. Standardized, it ranged from 0.16 to 0.32 units, which the authors translated to roughly 2.9 to 3.8 months of slower aging across the three years. Combining omega-3 with vitamin D and exercise added a little more.

This is the first randomized trial to show a supplement nudging these clocks, which is why it made news. But hold the caveats firmly. It was a post hoc analysis, meaning the clock question was asked after the trial, not the reason it was built. The effect is measured in months, not years. And epigenetic clocks are surrogate markers: we believe they reflect aging, but no one has yet shown that slowing one by three months makes a person live longer or healthier. The parent DO-HEALTH trial, published in JAMA in 2020, found no significant benefit of omega-3 on the actual clinical outcomes it was built to measure, things like fractures, infections, and blood pressure.

So omega-3 may slow a clock we use to estimate aging. Whether that turns into a longer life is exactly the question the hard-outcome trials were designed to answer.

But Does It Prevent Heart Attacks? The Trials That Matter

This is where the story gets honest, because the biggest and best-designed trials mostly disappointed.

VITAL was the landmark. Published in the New England Journal of Medicine in 2019 and led by JoAnn Manson, it randomized 25,871 healthy U.S. adults to one gram of fish oil a day or placebo, then followed them for a median of 5.3 years. The result on its primary endpoint was null: major cardiovascular events showed a hazard ratio of 0.92, with a confidence interval, 0.80 to 1.06, that comfortably crossed 1.0. Fish oil did not prevent cardiovascular disease or cancer overall. There was one interesting secondary signal: heart attacks specifically dropped, with a hazard ratio of 0.72.

ASCEND told a similar story in a higher-risk group. Also in the New England Journal of Medicine, in 2018, it gave one gram of omega-3 a day to 15,480 people with diabetes and followed them for an average of 7.4 years. Serious vascular events came out essentially even: a rate ratio of 0.97, confidence interval 0.87 to 1.08. Null again.

Maybe the dose was too low? STRENGTH tested that. Published in JAMA in 2020 and led by Steven Nicholls, it gave 13,078 high-risk patients a full 4 grams a day of EPA and DHA, four times the usual dose, compared against corn oil. The trial was stopped early for futility. The hazard ratio was 0.99, confidence interval 0.90 to 1.09. High-dose fish oil did nothing for events here, and it caused more gastrointestinal side effects.

There is one trial that worked, and it's important to understand why it's different. REDUCE-IT, in the New England Journal of Medicine in 2019, led by Deepak Bhatt, gave 8,179 high-risk patients 4 grams a day of icosapent ethyl, a purified prescription form of EPA only. Cardiovascular events fell from 22.0 percent in the placebo group to 17.2 percent, a hazard ratio of 0.75, a real 25 percent relative reduction. But REDUCE-IT tested a drug, not a fish-oil capsule: a single, purified, high-dose EPA molecule. It also raised the risk of atrial fibrillation, and the way its results square with the null STRENGTH trial is still debated by cardiologists. The maker of the drug funded the study.

Two large meta-analyses tried to find the signal in the noise. A 2019 analysis in the Journal of the American Heart Association by Yang Hu and colleagues pooled 13 trials and 127,477 participants, and found that marine omega-3 was associated with a modest reduction in heart attack risk, about 8 percent, and in coronary heart disease death, with a roughly linear benefit at higher doses. The 2020 Cochrane review, the most rigorous synthesis, looked at 86 trials and 162,796 people. Its verdict was sober: long-chain omega-3 has little or no effect on overall mortality (relative risk 0.97, rated high-certainty) and only a slight effect on coronary events. The one thing it does reliably is lower triglycerides, by about 15 percent in a dose-dependent way.

Put the cardiovascular evidence together and it reads like this. A one-gram capsule won't prevent a first heart attack in most people. It nudges heart-attack risk down a little, reliably lowers triglycerides, and that's about it. The dramatic result belongs to a high-dose prescription drug, which is a medical decision, not a supplement-aisle one.

What About the Brain, Muscle, and Inflammation?

Omega-3 gets sold for the aging brain most of all. DHA is a building block of neurons, so the logic is appealing. The trials, unfortunately, don't back the pill.

The largest synthesis, a 2020 meta-analysis in the Journal of the American Medical Directors Association by Julii Brainard and colleagues, pooled 38 trials and 49,757 participants. Its conclusion was blunt: long-chain omega-3 supplements do not protect older adults from cognitive decline (relative risk near 0.98). The big dedicated trial agrees. MAPT, published in Lancet Neurology in 2017, gave 1,680 older adults with memory complaints omega-3, 800 mg of DHA plus 225 mg of EPA a day, for three years, and found no significant difference in cognitive decline (omega-3 alone, p = 0.812).

Muscle is more encouraging, on a smaller scale. A 2015 trial in the American Journal of Clinical Nutrition by Gordon Smith gave 60 healthy adults aged 60 to 85 fish oil for six months. Thigh muscle volume rose 3.6 percent, handgrip strength rose 2.3 kilograms, and one-rep-max strength rose 4.0 percent, all statistically significant against placebo. An earlier study from the same group, in 2011, had shown the mechanism: omega-3 raised the rate of muscle protein synthesis in older adults. The caveat is durability. The DO-HEALTH trial, in a 2025 analysis in the Journal of the American Geriatrics Society, found omega-3 helped preserve lean mass at year one, but the advantage washed out by year three. And a separate analysis of the VITAL trial, in JAMA Network Open in 2022, found omega-3 did not reduce the risk of becoming frail.

Inflammation is where omega-3 shows its cleanest small-scale effect. In a 2011 randomized trial in Brain, Behavior, and Immunity, Kiecolt-Glaser's team gave 68 medical students 2.5 grams a day of omega-3. The supplement lowered stimulated production of the inflammatory marker IL-6 by 14 percent, and cut anxiety symptoms by 20 percent. That fits the membrane-and-signaling biology, even if it's a long way from preventing disease.

What's Settled and What Isn't

It helps to separate the solid from the wishful.

What the evidence backs up:

• Omega-3 reliably lowers triglycerides, by about 15 percent, in a dose-dependent way (Cochrane, 86 trials).
• People with higher blood omega-3 levels consistently live longer across large cohorts, by 15 to 34 percent depending on the study.
• At one gram a day, omega-3 modestly lowers heart-attack risk specifically, even though it doesn't move broader cardiovascular events.
• Omega-3 supplements are safe and well tolerated at standard doses.

What remains uncertain or unsupported:

• Whether a fish-oil capsule slows human aging in any way that adds healthy years. The epigenetic-clock result is real but small, surrogate, and post hoc.
• Whether the long-life association is omega-3 itself or just a marker of people who eat fish and live well. Only a trial can separate those, and the trials are mostly null.
• The brain claim. The large cognition trials show no protection from decline.
• The right dose. One gram does little for events, four grams of ordinary fish oil also did little, and only a purified prescription drug at four grams clearly worked.
• The founding story itself. Omega-3's reputation grew from 1970s observations of Greenland Inuit, but a 2014 reappraisal found those studies never measured heart disease directly, and later work finds Inuit populations get coronary disease about as often as anyone else.

How to Think About It

If you're a science-minded person deciding what to do, here's a reasonable read.

The strongest human data measured fish, not capsules. The cohorts that found lower mortality were tracking people who ate oily fish, salmon, sardines, mackerel, a couple of times a week. That food carries the omega-3 plus protein, plus vitamin D, plus everything else that comes with replacing processed meat at dinner. The simplest evidence-based move is the plate, the same conclusion most nutrition research keeps reaching.

A one-gram supplement is a reasonable, safe choice if you don't eat fish, and it reliably helps one number, triglycerides. Just hold realistic expectations. In the big trials it did not prevent heart attacks and strokes in general, and it did not protect memory.

If your triglycerides are high and your cardiovascular risk is high, the 4-gram purified EPA drug (icosapent ethyl) is a real option, but that's a prescription decision to make with a doctor, weighing the atrial-fibrillation risk. It is not the same as buying a bigger bottle of fish oil.

The biological-aging angle, the clocks and the telomeres, is worth watching rather than acting on. It's the frontier of this research, not a settled reason to take a pill. The most dependable levers on aging are still the unglamorous ones: regular exercise, good sleep, not smoking, and a diet built around whole foods and fish.

Talk to your doctor before starting omega-3 at high doses, especially if you take blood thinners, since high doses can affect bleeding and heart rhythm. This article is for understanding the science, not for replacing medical advice.

Frequently Asked Questions

Does fish oil prevent heart attacks? Mostly no, at supplement doses. The two largest prevention trials, VITAL (25,871 people) and ASCEND (15,480 people with diabetes), found that one gram a day did not lower overall cardiovascular events. A 4-gram fish-oil trial, STRENGTH, was also null. Heart attacks specifically did drop a little in VITAL, a 28 percent relative reduction. The one trial showing a clear benefit, REDUCE-IT, used a 4-gram purified prescription EPA drug, not an ordinary fish-oil capsule.

Can omega-3 actually slow aging? There's an early signal, not a settled answer. A 2025 analysis of the DO-HEALTH trial in Nature Aging found that one gram of omega-3 a day slowed several epigenetic aging clocks by the equivalent of about 2.9 to 3.8 months over three years. That's a real result, but it was a post hoc analysis, the effect was small, and these clocks are estimates of aging, not proof of a longer life. No trial has shown that omega-3 extends human lifespan.

Is it better to eat fish or take fish oil? The strongest evidence comes from eating fish. The cohort studies that linked omega-3 to lower mortality measured blood levels and fish intake, not supplements. Oily fish like salmon and sardines also deliver protein, vitamin D, and other nutrients. A supplement is a reasonable backup if you don't eat fish, and it reliably lowers triglycerides, but the food version has the better track record.

What is the Omega-3 Index, and what's a good level? The Omega-3 Index is the percentage of EPA plus DHA in your red blood cell membranes, a measure of long-term intake rather than a single meal. In the Framingham Heart Study, people with an index above 6.8 percent had a 34 percent lower risk of death than those below 4.2 percent. It's available as a blood test, though the company that popularized the test has a commercial interest in it.

Is fish oil safe? At standard doses, about one gram a day, omega-3 is safe and well tolerated, with no serious safety signals across very large trials. At high doses, 4 grams, there's a measurable increase in atrial fibrillation, an irregular heart rhythm, seen in both REDUCE-IT and STRENGTH, plus a possible effect on bleeding. If you take blood thinners or have a heart-rhythm condition, talk to your doctor before taking high doses.

Sources

1. Harris WS, Tintle NL, Etherton MR, Vasan RS. (2018). "Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study." Journal of Clinical Lipidology, 12(3), 718-727. PubMed: 29559306
2. Harris WS, Tintle NL, Imamura F, et al. (2021). "Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies." Nature Communications, 12(1), 2329. PubMed: 33888689
3. Farzaneh-Far R, Lin J, Epel ES, et al. (2010). "Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease." JAMA, 303(3), 250-257. PubMed: 20085953
4. Kiecolt-Glaser JK, Epel ES, Belury MA, et al. (2013). "Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial." Brain, Behavior, and Immunity, 28, 16-24. PubMed: 23010452
5. Bischoff-Ferrari HA, Gängler S, Wieczorek M, et al. (2025). "Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial." Nature Aging, 5(3), 376-385. PubMed: 39900648
6. Manson JE, Cook NR, Lee IM, et al. (2019). "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." New England Journal of Medicine, 380(1), 23-32. PubMed: 30415637
7. Bowman L, Mafham M, Wallendszus K, et al. (2018). "Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus." New England Journal of Medicine, 379(16), 1540-1550. PubMed: 30146932
8. Nicholls SJ, Lincoff AM, Garcia M, et al. (2020). "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial." JAMA, 324(22), 2268-2280. PubMed: 33190147
9. Bhatt DL, Steg PG, Miller M, et al. (2019). "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." New England Journal of Medicine, 380(1), 11-22. PubMed: 30415628
10. Hu Y, Hu FB, Manson JE. (2019). "Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants." Journal of the American Heart Association, 8(19), e013543. PubMed: 31567003
11. Abdelhamid AS, Brown TJ, Brainard JS, et al. (2020). "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease." Cochrane Database of Systematic Reviews, 3, CD003177. PubMed: 32114706
12. Brainard JS, Jimoh OF, Deane KHO, et al. (2020). "Omega-3, Omega-6, and Polyunsaturated Fat for Cognition: Systematic Review and Meta-analysis of Randomized Trials." Journal of the American Medical Directors Association, 21(10), 1439-1450. PubMed: 32305302
13. Andrieu S, Guyonnet S, Coley N, et al. (2017). "Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial." Lancet Neurology, 16(5), 377-389. PubMed: 28359749
14. Smith GI, Julliand S, Reeds DN, et al. (2015). "Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults." American Journal of Clinical Nutrition, 102(1), 115-122. PubMed: 25994567
15. Smith GI, Atherton P, Reeds DN, et al. (2011). "Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial." American Journal of Clinical Nutrition, 93(2), 402-412. PubMed: 21159787
16. Kiecolt-Glaser JK, Belury MA, Andridge R, et al. (2011). "Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial." Brain, Behavior, and Immunity, 25(8), 1725-1734. PubMed: 21784145
17. Eggimann AK, de Godoi Rezende Costa Molino C, Freystaetter G, et al. (2025). "Effect of vitamin D, omega-3 supplementation, or a home exercise program on muscle mass and sarcopenia: DO-HEALTH trial." Journal of the American Geriatrics Society, 73(4), 1049-1059. PubMed: 39565152
18. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. (2020). "Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial." JAMA, 324(18), 1855-1868. PubMed: 33170239
19. Orkaby AR, Dushkes R, Ward R, et al. (2022). "Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial." JAMA Network Open, 5(9), e2231206. PubMed: 36098968
20. Dyerberg J, Bang HO, Hjorne N. (1975). "Fatty acid composition of the plasma lipids in Greenland Eskimos." American Journal of Clinical Nutrition, 28(9), 958-966. PubMed: 1163480
21. Bang HO, Dyerberg J, Hjorne N. (1976). "The composition of food consumed by Greenland Eskimos." Acta Medica Scandinavica, 200(1-2), 69-73. PubMed: 961471
22. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. (1978). "Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?" The Lancet, 2(8081), 117-119. PubMed: 78322
23. Kromann N, Green A. (1980). "Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974." Acta Medica Scandinavica, 208(5), 401-406. PubMed: 7457208
24. GISSI-Prevenzione Investigators. (1999). "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial." The Lancet, 354(9177), 447-455. PubMed: 10465168
25. Simopoulos AP. (2002). "The importance of the ratio of omega-6/omega-3 essential fatty acids." Biomedicine & Pharmacotherapy, 56(8), 365-379. PubMed: 12442909
26. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. (2011). "Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century." American Journal of Clinical Nutrition, 93(5), 950-962. PubMed: 21367944
27. Fodor JG, Helis E, Yazdekhasti N, Vohnout B. (2014). "'Fishing' for the origins of the 'Eskimos and heart disease' story: facts or wishful thinking?" Canadian Journal of Cardiology, 30(8), 864-868. PubMed: 25064579

Funding Transparency

LSD is editorially independent. We receive no funding from pharmaceutical, supplement, or longevity companies. In the interest of full transparency, here are the funding and conflict relationships behind the research cited above:

• Sources #1 and #2 (the Harris cohort work): William Harris co-founded and holds an equity interest in OmegaQuant, the company that sells the Omega-3 Index blood test. His cohort analyses consistently support the value of measuring omega-3 levels, so readers should weigh that interest. The underlying cohorts (the Framingham Heart Study and the 17 pooled studies) were supported by public research funding.
• Source #5 (the DNA methylation clock analysis): One author, Steve Horvath, is a developer of the epigenetic clocks used as the outcome, a founder of the nonprofit Epigenetic Clock Development Foundation, which licenses clock patents, and an employee of Altos Labs, a longevity company. The clocks are his life's work, which is fair context for a result measured entirely in those clocks.
• Source #9 (REDUCE-IT): This trial was funded by Amarin Pharma, the maker of icosapent ethyl (Vascepa), the drug it tested. That is a direct commercial interest in a positive result, and the trial was positive. It doesn't invalidate the finding, but it is the strongest conflict on this list, and part of why the result is still debated against the null STRENGTH trial.
• Source #8 (STRENGTH): Funded by AstraZeneca, which was developing a competing omega-3 product. This trial was null.
• Sources #6, #18, #19 (VITAL and the DO-HEALTH parent trial): VITAL was funded mainly by the U.S. National Institutes of Health, with fish oil and matching placebo donated by Pronova BioPharma and BASF. DO-HEALTH was funded largely by European public sources and a European Commission grant. Product donations are routine for supplement trials and don't appear to have shaped what were largely null clinical results.
• Source #7 (ASCEND): Funded mainly by the British Heart Foundation and other non-commercial sources, with study capsules supplied by industry.
• Sources #20 to #23 (the founding Inuit studies, 1975 to 1980): The Bang and Dyerberg blood-fat surveys and the Greenland disease-incidence reports that launched the field. These were academic studies with no supplement industry behind them, but they predate modern conflict-of-interest norms, and source #27 is the later reappraisal showing they never directly measured heart disease.
• Source #24 (GISSI-Prevenzione): An Italian academic and government collaborative trial. Capsules were supplied by industry, the standard pattern for supplement trials. This is the large trial that, for years, anchored the belief that fish oil protects the heart.
• Source #25 (the omega-6 to omega-3 ratio review): A single-author review advancing the "ratio" hypothesis, a framework its author has long championed. We cite it to explain why the modern diet got framed as omega-3 deficient, not as settled consensus. The deficiency narrative is contested.
• Source #26 (Blasbalg, 20th-century fatty-acid intake): Authored by scientists at the U.S. National Institutes of Health and supported by public funding. It documents the soybean-oil shift without a commercial interest.
• Source #27 (the Fodor reappraisal): Academic cardiology, no supplement-industry interest. This is the skeptical counterweight to the founding story, and we lean on it deliberately to keep the origin claim honest.
• General: The remaining meta-analysis, cognition, muscle, and inflammation studies were largely supported by public and academic funding based on the disclosures we reviewed.

Related Reading

• Inflammation and Aging - The smoldering, low-grade inflammation that omega-3 helps quiet, and why it sits near the center of aging.
• The 12 Hallmarks of Aging - Where telomere shortening and the epigenetic clocks fit into the bigger picture of why we age.
• Nutrition and Longevity - Why eating fish beats taking fish oil, and what the strongest dietary evidence actually shows.
• Spermidine and Longevity - Another supplement where the biology is strong but the human trials are still thin.
• Your Body's Biomarkers - How measures like the Omega-3 Index fit into tracking your own aging.

This article is for education, not medical advice. Omega-3 supplements have not been shown to prevent heart disease or protect memory in healthy people. Talk to your doctor before starting any supplement, especially at high doses or if you take blood thinners.

Written with the help of AI tools, shaped and verified by humans who care about getting this right.